Longitudinal changes in credit status for newly diagnosed metastatic colorectal cancer patients (SWOG S1417).

C C. Natasha Kwendakwema (Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA) A Amy Darke (SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA) J Joseph M. Unger (Public Health Sciences Division Fred Hutchinson Cancer Center Seattle Washington USA) D Dawn L. Hershman (Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center New York New York USA) S Scott David Ramsey (Fred Hutch Cancer Center, Seattle, WA) V Veena Shankaran (1Fred Hutchinson Cancer Center, Seattle, United States)

Abstract

11076 Background: We previously reported that 71% of insured patients with newly diagnosed metastatic colorectal cancer (mCRC) self-reported major financial hardship (MFH), defined as one or more of increased debt, new loans from family and/or friends, selling or refinancing a home, or 20% or more income decline, within 12 months of diagnosis. In this secondary analysis using credit data, we examined if enrolled patients experienced changes in credit status over time. Methods: Depersonalized credit data were obtained from TransUnion, one of the largest credit agencies in the United States, at enrollment, 6, and 12 months. Patients with a baseline and at least one follow-up credit record were analyzed. Demographic data were obtained from questionnaires at enrollment. We determined the mean number or proportion of patients with adverse credit events (defined as past due or delinquent credit cards or mortgage payments, third-party collections, tax liens, charge-offs, bankruptcies, foreclosures, or repossessions) and the mean past due credit card amount, if applicable, at baseline and follow-up. We used paired t-tests to compare credit characteristics between baseline and follow-up in the entire cohort and in subgroups with and without MFH. Multivariate logistic regression was used to identify factors associated with adverse credit events. Results: 318 patients were analyzed (median age 59.1, 41% female, 80% white, 59% married, 42% with private health insurance). Approximately 3.4% of patients experienced a new adverse credit event during the study period, 143 (45.0%) patients at baseline and 154 (48.4%) at follow-up (p=0.07). Overall, new adverse credit events were uncommon and only third-party collections significantly worsened over time (mean 3.20 (SD 3.17) at baseline and mean 4.11 (SD 3.85) at follow-up; p < 0.001). Charge-offs numerically increased over time, but the value did not reach significance. On average, past due amounts on open credit cards increased over time ($100.60 at baseline and $291.33 at follow-up), with the increase largely seen among patients self-reporting MFH. Adverse credit events were more likely to worsen in patients who were younger (OR 2.51, CI 1.08-5.84), had lower household income (OR 3.09, CI 1.07-8.92), lower educational status (OR 2.07, CI 1.10-3.88), and fewer assets, defined as less than $100,000 (OR 4.15, CI 1.58-10.91). Conclusions: Despite high levels of self-reported MFH in this cohort, credit data showed no significant increase in adverse credit events between baseline and follow-up, except for increased third-party collections and total past due credit card balances. This may be due to credit reports capturing only more severe financial impacts or because the impacts of financial hardship take longer to be reflected in credit reports. A future study will examine how patients leverage credit, such as applying for new credit cards or reaching credit limits.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 11076-11076
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (6)

C

C. Natasha Kwendakwema

Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA

A

Amy Darke

SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA

J

Joseph M. Unger

Public Health Sciences Division Fred Hutchinson Cancer Center Seattle Washington USA

D

Dawn L. Hershman

Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center New York New York USA

S

Scott David Ramsey

Fred Hutch Cancer Center, Seattle, WA

V

Veena Shankaran

1Fred Hutchinson Cancer Center, Seattle, United States